This report aims to provide a comprehensive presentation of the global market for Next-Generation Breast Cancer Diagnostic and Screening, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Breast Cancer Diagnostic and Screening. This report contains market size and forecasts of Next-Generation Breast Cancer Diagnostic and Screening in global, including the following market information:
Global Next-Generation Breast Cancer Diagnostic and Screening Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Next-Generation Breast Cancer Diagnostic and Screening market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Real-Time PCR (q-PCR) Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Next-Generation Breast Cancer Diagnostic and Screening include Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation and EXACT Sciences Corporation, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Next-Generation Breast Cancer Diagnostic and Screening companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Next-Generation Breast Cancer Diagnostic and Screening Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, by Type, 2022 (%)
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)
Global Next-Generation Breast Cancer Diagnostic and Screening Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, by Application, 2022 (%)
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers
Global Next-Generation Breast Cancer Diagnostic and Screening Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Next-Generation Breast Cancer Diagnostic and Screening Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Next-Generation Breast Cancer Diagnostic and Screening revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Next-Generation Breast Cancer Diagnostic and Screening revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Next-Generation Breast Cancer Diagnostic and Screening, market overview.
Chapter 2: Global Next-Generation Breast Cancer Diagnostic and Screening market size in revenue.
Chapter 3: Detailed analysis of Next-Generation Breast Cancer Diagnostic and Screening company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Next-Generation Breast Cancer Diagnostic and Screening in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Next-Generation Breast Cancer Diagnostic and Screening Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Next-Generation Breast Cancer Diagnostic and Screening Overall Market Size
2.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2022 VS 2029
2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
3.2 Top Global Next-Generation Breast Cancer Diagnostic and Screening Companies Ranked by Revenue
3.3 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies
3.4 Top 3 and Top 5 Next-Generation Breast Cancer Diagnostic and Screening Companies in Global Market, by Revenue in 2022
3.5 Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type
3.6 Tier 1, Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market
3.6.1 List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies
3.6.2 List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size Markets, 2022 & 2029
4.1.2 Real-Time PCR (q-PCR)
4.1.3 Immunohistochemistry (IHC)
4.1.4 Next-Generation Sequencing (NGS)
4.1.5 Fluorescent In-Situ Hybridization (FISH)
4.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
4.2.1 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2023
4.2.2 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2024-2029
4.2.3 By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2022 & 2029
5.1.2 Hospital-associated Labs
5.1.3 Cancer Research Institutes
5.1.4 Diagnostic Centers
5.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
5.2.1 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2023
5.2.2 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2024-2029
5.2.3 By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2022 & 2029
6.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue & Forecasts
6.2.1 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2023
6.2.2 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2024-2029
6.2.3 By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2029
6.3.2 US Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2029
6.4.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4.4 U.K. Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4.5 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4.6 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4.7 Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.4.8 Benelux Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2029
6.5.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.5.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.5.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.5.5 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.5.6 India Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2029
6.6.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.6.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2029
6.7.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.7.3 Israel Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.7.4 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
6.7.5 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size, 2018-2029
7 Next-Generation Breast Cancer Diagnostic and Screening Companies Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Company Summary
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.1.5 Abbott Laboratories Key News & Latest Developments
7.2 Agendia
7.2.1 Agendia Company Summary
7.2.2 Agendia Business Overview
7.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.2.5 Agendia Key News & Latest Developments
7.3 Agilent Technologies
7.3.1 Agilent Technologies Company Summary
7.3.2 Agilent Technologies Business Overview
7.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.3.5 Agilent Technologies Key News & Latest Developments
7.4 Ambry Genetics
7.4.1 Ambry Genetics Company Summary
7.4.2 Ambry Genetics Business Overview
7.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.4.5 Ambry Genetics Key News & Latest Developments
7.5 Biocept
7.5.1 Biocept Company Summary
7.5.2 Biocept Business Overview
7.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.5.5 Biocept Key News & Latest Developments
7.6 Biotheranostics
7.6.1 Biotheranostics Company Summary
7.6.2 Biotheranostics Business Overview
7.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.6.5 Biotheranostics Key News & Latest Developments
7.7 Centogene
7.7.1 Centogene Company Summary
7.7.2 Centogene Business Overview
7.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.7.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.7.5 Centogene Key News & Latest Developments
7.8 Danaher Corporation
7.8.1 Danaher Corporation Company Summary
7.8.2 Danaher Corporation Business Overview
7.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.8.5 Danaher Corporation Key News & Latest Developments
7.9 EXACT Sciences Corporation
7.9.1 EXACT Sciences Corporation Company Summary
7.9.2 EXACT Sciences Corporation Business Overview
7.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.9.5 EXACT Sciences Corporation Key News & Latest Developments
7.10 Roche Holding AG
7.10.1 Roche Holding AG Company Summary
7.10.2 Roche Holding AG Business Overview
7.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.10.5 Roche Holding AG Key News & Latest Developments
7.11 Fulgent Genetics
7.11.1 Fulgent Genetics Company Summary
7.11.2 Fulgent Genetics Business Overview
7.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.11.5 Fulgent Genetics Key News & Latest Developments
7.12 Illumina
7.12.1 Illumina Company Summary
7.12.2 Illumina Business Overview
7.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.12.5 Illumina Key News & Latest Developments
7.13 Invitae
7.13.1 Invitae Company Summary
7.13.2 Invitae Business Overview
7.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.13.5 Invitae Key News & Latest Developments
7.14 Lucence Diagnostics Pte Ltd
7.14.1 Lucence Diagnostics Pte Ltd Company Summary
7.14.2 Lucence Diagnostics Pte Ltd Business Overview
7.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.14.5 Lucence Diagnostics Pte Ltd Key News & Latest Developments
7.15 Myriad Genetics
7.15.1 Myriad Genetics Company Summary
7.15.2 Myriad Genetics Business Overview
7.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Major Product Offerings
7.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global Market (2018-2023)
7.15.5 Myriad Genetics Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Next-Generation Breast Cancer Diagnostic and Screening Market Opportunities & Trends in Global Market
Table 2. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers in Global Market
Table 3. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints in Global Market
Table 4. Key Players of Next-Generation Breast Cancer Diagnostic and Screening in Global Market
Table 5. Top Next-Generation Breast Cancer Diagnostic and Screening Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Companies, 2018-2023
Table 8. Global Companies Next-Generation Breast Cancer Diagnostic and Screening Product Type
Table 9. List of Global Tier 1 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Next-Generation Breast Cancer Diagnostic and Screening Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Next-Generation Breast Cancer Diagnostic and Screening Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2024-2029
Table 30. Abbott Laboratories Company Summary
Table 31. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 32. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 33. Abbott Laboratories Key News & Latest Developments
Table 34. Agendia Company Summary
Table 35. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 36. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 37. Agendia Key News & Latest Developments
Table 38. Agilent Technologies Company Summary
Table 39. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 40. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 41. Agilent Technologies Key News & Latest Developments
Table 42. Ambry Genetics Company Summary
Table 43. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 44. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 45. Ambry Genetics Key News & Latest Developments
Table 46. Biocept Company Summary
Table 47. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 48. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 49. Biocept Key News & Latest Developments
Table 50. Biotheranostics Company Summary
Table 51. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 52. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 53. Biotheranostics Key News & Latest Developments
Table 54. Centogene Company Summary
Table 55. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 56. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 57. Centogene Key News & Latest Developments
Table 58. Danaher Corporation Company Summary
Table 59. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 60. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 61. Danaher Corporation Key News & Latest Developments
Table 62. EXACT Sciences Corporation Company Summary
Table 63. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 64. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 65. EXACT Sciences Corporation Key News & Latest Developments
Table 66. Roche Holding AG Company Summary
Table 67. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 68. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 69. Roche Holding AG Key News & Latest Developments
Table 70. Fulgent Genetics Company Summary
Table 71. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 72. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 73. Fulgent Genetics Key News & Latest Developments
Table 74. Illumina Company Summary
Table 75. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 76. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 77. Illumina Key News & Latest Developments
Table 78. Invitae Company Summary
Table 79. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 80. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 81. Invitae Key News & Latest Developments
Table 82. Lucence Diagnostics Pte Ltd Company Summary
Table 83. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 84. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 85. Lucence Diagnostics Pte Ltd Key News & Latest Developments
Table 86. Myriad Genetics Company Summary
Table 87. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product Offerings
Table 88. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (US$, Mn) & (2018-2023)
Table 89. Myriad Genetics Key News & Latest Developments
List of Figures
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Segment by Type in 2022
Figure 2. Next-Generation Breast Cancer Diagnostic and Screening Segment by Application in 2022
Figure 3. Global Next-Generation Breast Cancer Diagnostic and Screening Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Next-Generation Breast Cancer Diagnostic and Screening Revenue in 2022
Figure 8. By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 9. By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 10. By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 12. By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 14. By Region - Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 15. By Country - North America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 16. US Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 20. Germany Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 21. France Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 28. China Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 32. India Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 34. Brazil Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share, 2018-2029
Figure 37. Turkey Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Next-Generation Breast Cancer Diagnostic and Screening Revenue, (US$, Mn), 2018-2029
Figure 41. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
